The Compounding Disclosure Test: Auditing How Platforms Explain FDA Status
Published September 2026 · Investigative audit · 9 min read
The FDA's February and March 2026 warning letters cited a specific violation pattern: telehealth platforms describing their compounded GLP-1 medications using language that implies FDA approval. Phrases like "same active ingredient as Wegovy" and "generic Ozempic" appeared across dozens of platforms — and the FDA said, in writing, that these claims are misleading because compounded drugs are not FDA-approved and have not been evaluated for safety or effectiveness.
We conducted our own audit: visiting the websites of 20+ GLP-1 telehealth platforms and evaluating how each one explains the FDA status of their compounded medications to potential customers. What we found ranges from exemplary transparency to what can only be described as deliberate obfuscation.
What the Law Requires
The legal requirement is clear: compounded medications are not FDA-approved, and any marketing that implies otherwise violates the Federal Food, Drug, and Cosmetic Act. Specifically, Section 502(a) prohibits labeling that is "false or misleading in any particular," and Section 502(bb) prohibits promotion of compounded drugs using claims that misleadingly suggest FDA approval.
In practice, this means platforms should clearly state that their compounded semaglutide or tirzepatide is not the same product as Wegovy, Ozempic, Mounjaro, or Zepbound. They should acknowledge that compounded drugs have not been evaluated by the FDA for safety, effectiveness, or quality. And they should not use brand names in a way that implies their product is a generic version of those brands — because FDA-approved generics go through a formal approval process that compounded drugs do not.
The Grading Scale
We evaluated each platform on a four-tier scale based on the clarity, accuracy, and prominence of their compounding disclosures.
Grade A: Transparent and Prominent
The platform clearly states that its medications are compounded, not FDA-approved, and not equivalent to brand-name products. This disclosure appears on the homepage, product pages, and during the checkout/intake process — not buried in a Terms of Service page that no consumer reads. The language is plain, not legalistic, and doesn't require interpretation.
What this looks like: "Our semaglutide is compounded by [named pharmacy] and is not FDA-approved. It contains the same active ingredient as Ozempic and Wegovy, but it is not the same product and has not been evaluated by the FDA for safety or effectiveness." — visible on the product page, above the fold or in an unmissable disclosure box.
Grade B: Accurate but Buried
The disclosure exists and is accurate, but you have to look for it. It's in the footer, the FAQ, or the Terms of Service rather than on the product page itself. A consumer who reads carefully will find it, but a consumer who scrolls straight to "Get Started" may never see it.
What this looks like: Accurate FDA disclaimer in the footer or FAQ, but the product page uses language like "clinically proven weight loss medication" without the compounding context immediately adjacent. Technically compliant, practically incomplete.
Grade C: Misleading by Omission
The platform does not proactively disclose that its medications are compounded. A consumer could complete the entire signup process without encountering the word "compounded" or the phrase "not FDA-approved." The site may not make false claims, but it strategically omits the information that would contextualize its product as fundamentally different from the brand-name drugs consumers have heard about on TV.
What this looks like: The product page says "semaglutide" without any qualifier. No mention of compounding. No mention of FDA status. The consumer assumes they're getting the same thing their doctor would prescribe. They're not.
Grade F: Actively Misleading
The platform uses language that implies FDA approval, brand-name equivalence, or "generic" status. This includes phrases like "same as Wegovy," "generic Ozempic," "FDA-approved semaglutide" (when referring to compounded product), or displaying brand-name logos alongside their compounded products. This is precisely the conduct the FDA cited in its 2025–2026 warning letters.
What this looks like: "Get the same weight loss medication used in clinical trials — at a fraction of the cost" next to images of Wegovy pens, with no disclosure that the product is compounded. Or: "MEDVi" printed on the vial label as though MEDVi is the manufacturer — the specific violation cited in MEDVi's February 2026 warning letter.
What We Found
Without naming every platform individually (some may have updated their disclosures since our audit), the distribution was concerning. Roughly 20–25% of platforms we reviewed earned a Grade A — clear, prominent, accurate disclosures that a consumer couldn't miss. About 30–35% earned a Grade B — accurate information that required effort to find. Another 25–30% earned a Grade C — strategic omission that left consumers uninformed. And approximately 10–15% earned a Grade F — language that either explicitly or implicitly misled consumers about what they were buying.
The Grade F platforms were concentrated among the companies that have already received FDA warning letters. But not exclusively — some platforms without warning letters use language that, in our assessment, would be vulnerable to the same enforcement actions if the FDA chose to pursue them.
Why This Matters Beyond Legality
Compounding disclosure isn't just a legal box to check. It's a clinical safety issue. Patients who don't understand that their medication is compounded may not understand why their prescriber can't look up their specific formulation in a drug interaction database. They may not understand why their medication doesn't come with the same patient information sheet as the brand-name version. They may not know to ask about potency testing, beyond-use dating, or pharmacy accreditation — questions that are essential for compounded medications and irrelevant for FDA-approved ones.
A platform that doesn't disclose compounding status isn't just violating FDA rules. It's preventing its patients from asking the right questions about their own care.
Grade A platforms from our audit
Sesame Care — Not compounded at all
FDA-approved brand-name medications only. Wegovy pill from $149/mo. The disclosure question doesn't apply because no compounding occurs.
See Sesame →Embody — Clear compounding disclosure
Injectable semaglutide $69–99 intro (ongoing ~$299/mo). Names pharmacy partners, discloses compounded status prominently.
See Embody →Compounded — not FDA-approved.
GobyMeds — Transparent on compounding + no subscription traps
Semaglutide from $99/mo. No auto-renew, overnight refrigerated shipping.
See GobyMeds →Compounded — not FDA-approved.
How to Check Any Platform Yourself
You don't need to wait for our audit. Open the platform's website and search for these terms: "compounded," "not FDA-approved," "503A" or "503B," and the name of their compounding pharmacy. If you can find clear answers to all four within two minutes of browsing, the platform is at least Grade B. If you can't find any of them, you're looking at a Grade C or F — and that tells you something about the company's relationship with transparency.
For a complete vetting framework, see our 20-Point Safe-Platform Checklist.